Fourth quarter and full year 2022 results

Fourth quarter and full-year 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Bill Sibold

Specialty Care

Olivier Charmeil

Olivier Charmeil

General Medicines

John Reed

John Reed

R&D

Thomas Triomphe

Thomas Triomphe

Vaccines

Julie Van Ongevalle

Julie Van Ongevalle

Consumer Healthcare

Roy Papatheodorou

Roy Papatheodorou

General Counsel

Highlights

With ten consecutive quarters of growth, the progress we’ve made in the past three years speaks for itself. As we launch the next phase of our strategy, our continued commitment to investing in the science will be crucial to maintaining a steady-state cadence of first and best in class medicines.
Paul Hudson

Paul Hudson

Chief Executive Officer, Sanofi

Downloads

Press release

Presentation

Q4 and FY 2022 Income statements, cash flow statements, balance sheet

Q4 and FY 2022 net sales by GBU, franchise, geographic region and product

R&D appendix

Download infographic

Q4 2022 Memorandum for modelling purposes

Contact

Investor Relations
investor.relations (at) sanofi.com 

More contact information